Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President
A new price grouping rule introduced for generic drugs last April has stirred up price competition and caused a “distortion in the market,” Japan Generic Medicines Association (JGA) President Itsuro Yoshida says. Because of the new rule, for example, some…
To read the full story
Related Article
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Gist of FY2014 NHI Price Revision
December 26, 2013
ORGANIZATION
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
- Five Groups Urge Action to Secure Medical Supplies amid Iran War
April 2, 2026
- JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
April 2, 2026
- UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
April 2, 2026
- JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…